[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100577789":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":11,"locations":17,"responsibleParty":36,"collaborators":10,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":40,"sex":45,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":10,"studyType":51,"phases":10,"briefSummary":52,"conditions":53,"keywords":63,"overallStatus":20,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"University of Tennessee Graduate School of Medicine","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":10},"Pregnant individuals at risk for preecampsia",null,[12],{"name":13,"role":14,"phone":15,"phoneExt":10,"email":16},"Jill M Maples, PhD","CONTACT","865-305-9367","jmaples1@utmck.edu",[18],{"facility":19,"status":20,"city":21,"state":22,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"University of Tennessee Medical Center","RECRUITING","Knoxville","Tennessee","37920","United States","US",{"type":27,"coordinates":28},"Point",[29,30],-83.92074,35.96064,{"lat":30,"lon":29},[33],{"name":34,"role":14,"phone":10,"phoneExt":10,"email":35},"Rebecca Purvis, MD","rpurvis@utmck.edu",{"type":37,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100577789","relationship-between-aspirin-metabolism-and-markers-of-metabolic-dysfunction-among-pregnant-persons-at-risk-of-pre-eclampsia-100577789",false,"NCT06802861","Relationship Between Aspirin Metabolism and Markers of Metabolic Dysfunction Among Pregnant Persons at Risk of Pre-eclampsia","RAMP","Inclusion Criteria:\n\n* Recommended aspirin for pre-eclampsia prevention by OB\u002FGYN or MFM specialist based on ACOG and USPSTF guidelines (1 high risk factor, 2+ moderate risk factors)\n\n  * Willingness to adhere to aspirin therapy\n  * Willingness to undergo 2h OGTT for serum and urine collection in addition to survey collection, indirect calorimetry, body composition measures, neonatal measures, etc.\n  * Gestational age at enrollment \\\u003C16 weeks\n  * Ability to speak, read, and communicate via English\n\nExclusion Criteria:\n\n* Type 2 Diabetes Mellitus\n\n  * Type 1 Diabetes Mellitus\n  * Current gestational diabetes mellitus\n  * Current\u002Factive platelet disorder or bleeding diathesis (thrombocytopenia of any etiology, idiopathic thrombocytopenic purpura\u002FITP, thrombotic thrombocytopenic purpura\u002FTTP, von Willebrand disease, etc.)\n  * Thrombophilia\n  * Current use of NSAID for other indication (indomethacin, ibuprofen, etc.)\n  * Current use of other immune-modulating agents and biologics (hydroxychloroquine, azathioprine, 6-mercaptopurine, IL-6 inhibitors, etc.)\n  * Current or recent use of steroids\n  * Current use of prophylactic or therapeutic anticoagulation\n  * Medical contraindication to aspirin therapy\n  * Molar pregnancy\n  * Renal disease\n  * Inability or unwillingness to give informed consent\n  * Current psychiatric illness\u002Fsocial situation that would limit compliance with study requirements, as determined by the principal investigators","FEMALE","18 Years","45 Years",{"count":49,"type":50},50,"ESTIMATED","OBSERVATIONAL","This study's primary purpose is to determine the relationship between aspirin metabolism and markers of metabolic dysfunction among patients at risk for preeclampsia.",[54,55,56,57,58,59,60,61,62],"Preeclampsia","Preeclampsia (PE)","Preeclampsia (PE) Risk","Obesity and Obesity-related Medical Conditions","Pregnancy","Pregnancy Complications","Gestational Diabetes","Gestational Diabetes Mellitus in Pregnancy","Gestational Complications",[64,65,66,67,68,69,70,71,72],"metabolic dysfunction","gestational diabetes","pregnancy","maternal obesity","maternal insulin resistance","aspirin metabolism","GDM","substrate oxidation","gestational glucose intolerance","2025-09-03",{"date":75,"type":76},"2025-09-10","ACTUAL",{"date":78,"type":76},"2025-01-01",{"date":80,"type":50},"2028-12-31",{"name":5,"class":6},1]